Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.11.2022 | Case report

Ciclosporin/cyclophosphamide/prednisone

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sato R, et al. [The efficacy of alemtuzumab for pure red cell aplasia associated with autoimmune polyendocrine syndrome type 1]. [Japanese]. Rinsho Ketsueki 63 : 189-193, No. 3, 2022. Available from: URL: http://doi.org/10.11406/rinketsu.63.189 [Japanese; summarised from a translation] Sato R, et al. [The efficacy of alemtuzumab for pure red cell aplasia associated with autoimmune polyendocrine syndrome type 1]. [Japanese]. Rinsho Ketsueki 63 : 189-193, No. 3, 2022. Available from: URL: http://​doi.​org/​10.​11406/​rinketsu.​63.​189 [Japanese; summarised from a translation]
Metadaten
Titel
Ciclosporin/cyclophosphamide/prednisone
Lack of efficacy: case report
Publikationsdatum
01.11.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-27547-0

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Duloxetine

Case report

Ropivacaine

Case report

Multiple drugs

Case report

Oxybutynin

Case report

Pazopanib